Revance Therapeutics, Inc. (RVNC): Price and Financial Metrics


Revance Therapeutics, Inc. (RVNC): $14.00

1.30 (+10.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RVNC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RVNC POWR Grades


  • Growth is the dimension where RVNC ranks best; there it ranks ahead of 63.17% of US stocks.
  • The strongest trend for RVNC is in Growth, which has been heading up over the past 179 days.
  • RVNC ranks lowest in Momentum; there it ranks in the 12th percentile.

RVNC Stock Summary

  • RVNC's price/sales ratio is 18.65; that's higher than the P/S ratio of 92.42% of US stocks.
  • As for revenue growth, note that RVNC's revenue has grown 407.65% over the past 12 months; that beats the revenue growth of 97.99% of US companies in our set.
  • In terms of volatility of its share price, RVNC is more volatile than 89.3% of stocks we're observing.
  • Stocks that are quantitatively similar to RVNC, based on their financial statements, market capitalization, and price volatility, are CLIR, AFIB, NCNO, FUV, and ACER.
  • Visit RVNC's SEC page to see the company's official filings. To visit the company's web site, go to www.revance.com.

RVNC Valuation Summary

  • In comparison to the median Healthcare stock, RVNC's EV/EBIT ratio is 124.23% lower, now standing at -7.1.
  • Over the past 92 months, RVNC's price/sales ratio has gone down 693.6.
  • Over the past 92 months, RVNC's price/sales ratio has gone down 693.6.

Below are key valuation metrics over time for RVNC.

Stock Date P/S P/B P/E EV/EBIT
RVNC 2021-08-31 40.9 10.3 -6.3 -7.1
RVNC 2021-08-30 41.0 10.4 -6.4 -7.1
RVNC 2021-08-27 41.7 10.5 -6.5 -7.2
RVNC 2021-08-26 41.4 10.5 -6.4 -7.2
RVNC 2021-08-25 41.8 10.6 -6.5 -7.2
RVNC 2021-08-24 41.4 10.5 -6.4 -7.2

RVNC Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -138.65%.
  • Its 2 year net income to common stockholders growth rate is now at -44.83%.
  • Its 5 year price growth rate is now at 6.83%.
Over the past 34 months, RVNC's revenue has gone up $73,985,000.

The table below shows RVNC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 77.798 -221.538 -281.31
2021-09-30 62.981 -239.241 -296.521
2021-06-30 47.071 -241.76 -303.402
2021-03-31 28.566 -209.968 -291.795
2020-12-31 15.325 -178.502 -282.089
2020-09-30 4.281 -149.696 -249.106

RVNC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RVNC has a Quality Grade of D, ranking ahead of 5.83% of graded US stocks.
  • RVNC's asset turnover comes in at 0.068 -- ranking 297th of 681 Pharmaceutical Products stocks.
  • HGEN, ZSAN, and ARMP are the stocks whose asset turnover ratios are most correlated with RVNC.

The table below shows RVNC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.068 0.694 -0.733
2021-03-31 0.043 0.685 -0.794
2020-12-31 0.024 0.689 -0.784
2020-09-30 0.008 0.742 -0.784
2020-06-30 0.001 0.957 -0.721
2020-03-31 0.001 1.000 -0.749

RVNC Price Target

For more insight on analysts targets of RVNC, see our RVNC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $39.78 Average Broker Recommendation 1.35 (Strong Buy)

RVNC Stock Price Chart Interactive Chart >

Price chart for RVNC

RVNC Price/Volume Stats

Current price $14.00 52-week high $33.83
Prev. close $12.70 52-week low $11.65
Day low $12.71 Volume 886,800
Day high $14.02 Avg. volume 709,354
50-day MA $17.08 Dividend yield N/A
200-day MA $17.98 Market Cap 1.02B

Revance Therapeutics, Inc. (RVNC) Company Bio


Revance Therapeutics is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company was founded in 1999 and is based in Newark, California.


RVNC Latest News Stream


Event/Time News Detail
Loading, please wait...

RVNC Latest Social Stream


Loading social stream, please wait...

View Full RVNC Social Stream

Latest RVNC News From Around the Web

Below are the latest news stories about Revance Therapeutics Inc that investors may wish to consider to help them evaluate RVNC as an investment opportunity.

State board grants incentives to four jobs deals, including a California HQ transplant doubling its pledged headcount

A publicly traded biotech company that moved headquarters from California to Nashville is doubling its jobs commitment to about 260 people, and doubling its state incentives as well. State officials on Wednesday approved the extra funding for Revance Therapeutics Inc. (Nasdaq: RVNC), as well as three other Greater Nashville jobs announcements.

Yahoo | February 23, 2022

Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

NASHVILLE, Tenn., February 22, 2022--Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Yahoo | February 22, 2022

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ...

Toronto, A6, based Investment company CIBC Asset Management Inc (Current Portfolio) buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, NVIDIA Corp, iShares MSCI EAFE ETF, sells Shaw Communications Inc, Progressive Corp, Visa Inc, Allegion PLC, Lightspeed Commerce Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CIBC Asset Management Inc.

Yahoo | February 8, 2022

Could The Revance Therapeutics, Inc. (NASDAQ:RVNC) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Revance Therapeutics, Inc. ( NASDAQ:RVNC ) can tell us which group is most powerful...

Yahoo | February 7, 2022

Read More 'RVNC' Stories Here

RVNC Price Returns

1-mo -15.61%
3-mo 4.48%
6-mo 12.36%
1-year -52.72%
3-year 26.13%
5-year -36.22%
YTD -14.22%
2021 -42.41%
2020 74.61%
2019 -19.37%
2018 -43.69%
2017 72.71%

Continue Researching RVNC

Here are a few links from around the web to help you further your research on Revance Therapeutics Inc's stock as an investment opportunity:

Revance Therapeutics Inc (RVNC) Stock Price | Nasdaq
Revance Therapeutics Inc (RVNC) Stock Quote, History and News - Yahoo Finance
Revance Therapeutics Inc (RVNC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5196 seconds.